Recombinant VWF antibody (AA 1815-1939)
-
- Target See all VWF Antibodies
- VWF (Von Willebrand Factor (VWF))
- Antibody Type
- Recombinant Antibody
-
Binding Specificity
- AA 1815-1939
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Monoclonal
-
Conjugate
- This VWF antibody is un-conjugated
-
Application
- Western Blotting (WB), Immunoprecipitation (IP), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Purification
- Purified
- Purity
- Protein A affinity chromatography
- Immunogen
- Amino acids 1815-1939 from the human protein were used as the immunogen for this recombinant vWF antibody.
- Clone
- VWF-1859R
- Isotype
- IgG kappa
- Top Product
- Discover our top product VWF Primary Antibody
-
-
- Application Notes
-
The optimal dilution of the recombinant vWF antibody for each application should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 1-2 μg/mL,Immunoprecipitation: 1-2 μg/500 μg lysate,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
- Preservative
- Azide free
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store the recombinant vWF antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
- Target
- VWF (Von Willebrand Factor (VWF))
- Alternative Name
- von Willebrand Factor / vWF (VWF Products)
- Synonyms
- VWF antibody, si:ch1073-474e24.1 antibody, F8VWF antibody, VWD antibody, 6820430P06Rik antibody, AI551257 antibody, B130011O06Rik antibody, C630030D09 antibody, von Willebrand factor antibody, Von Willebrand factor antibody, VWF antibody, vwf antibody, Vwf antibody
- Background
- Von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.
-